What Is the Omega-3 Index Test, and What Counts as a Healthy Score?

What this actually measures

The share of your red blood cells' membrane fatty acids made up specifically of EPA and DHA, the two long-chain omega-3s most studied for cardiovascular effects. Because red blood cells live roughly four months and build their membranes from whatever fatty acids are circulating while they're made, the result behaves like a rolling average of your intake over that period rather than a single day's blood draw.

What the test actually measures

An Omega-3 Index result is a single percentage: the share of EPA and DHA among all the fatty acids built into the membranes of your red blood cells. It is not a measurement of what’s currently floating loose in your plasma, and that distinction matters more than it sounds.

Red blood cells live for roughly four months before they’re broken down and replaced, and they build their membranes from whatever fatty acids are available in your bloodstream while they’re being made. Because a fresh batch of cells is always being produced as an older batch is retired, the fatty acid mix sitting in your red cells at any given moment behaves like a rolling average of what you’ve eaten over the past several months, rather than a snapshot of last night’s dinner. The researchers who proposed the test cited exactly this mechanism as the reason red blood cell composition reflects long-term EPA+DHA intake rather than a single meal.

That’s genuinely useful, and it’s also the test’s real advantage over a fasting lipid panel. A triglyceride reading can swing meaningfully depending on what you ate the evening before the blood draw. An Omega-3 Index typically doesn’t move much week to week, which makes it a steadier thing to track over months than most blood chemistry.

Where the “healthy” range actually comes from

Here’s the part worth sitting with before you interpret your own result: the reference bands popularly labeled “healthy” or “at risk” were proposed in a single 2004 paper, written by the two researchers who invented the metric.

William Harris and Clemens von Schacky examined the published coronary heart disease studies available at the time and found that the strongest cardioprotection tended to cluster around an index of 8% and above, while the weakest protection clustered around 4% and below. They proposed treating those two figures as risk thresholds — not because a regulatory body or a cardiology society had independently reviewed and endorsed them, but because that’s the pattern the existing data seemed to show when they looked.

That last row is the one most articles about this test skip past. It isn’t a criticism of the original researchers — proposing a threshold from the evidence available to you is exactly how risk factors get discovered in the first place — but it means a “good” Omega-3 Index is a research finding you’re applying to your own blood work, not a diagnostic cutoff that a guideline committee has signed off on the way it has for LDL cholesterol or blood pressure.

Why the same blood can score differently at two labs

Before this test had a standardized name, it had a standardization problem. Von Schacky’s own 2014 review reports that when a single blood sample was sent to five different laboratories offering an Omega-3 Index, the results differed by a factor of 3.5 — a gap wide enough, on its own, to move a person from one side of the 4%-8% zone to somewhere past the other.

That’s why a standardized version of the assay exists at all, with participating labs performing the kind of regular proficiency testing any accredited clinical chemistry lab is expected to run. It’s a real fix for a real problem. It also means that if you’re looking at a number from a lab that doesn’t disclose which method it used, or whether it participates in that proficiency testing, you should hold the exact decimal place more loosely than the report’s formatting implies.

Does raising the number actually lower your risk?

This is the question the test’s popularity quietly assumes an answer to, and it’s the one place the evidence gets genuinely uncomfortable.

The observational association is real. Across the cohort studies Harris and von Schacky reviewed, and in the epidemiological literature since, people with higher blood levels of EPA and DHA have consistently shown lower coronary risk than people with lower levels. But an observational association between a blood marker and an outcome is a different claim from “changing the marker changes the outcome,” and that’s exactly where the randomized-trial evidence gets weaker.

Cochrane’s 2020 systematic review pooled 86 randomized trials of omega-3 fatty acid intake and found high-certainty evidence that increasing EPA and DHA makes little to no difference to all-cause mortality. It found only low-certainty evidence of a slight reduction in coronary events — working out to roughly 334 people needing to increase their intake to prevent a single coronary death — and moderate-certainty evidence of little or no effect on stroke. The one high-certainty cardiovascular benefit it confirmed was a roughly 15% reduction in triglycerides: a real effect, but a narrower one than “raises your Omega-3 Index and protects your heart.”

Von Schacky’s own review is candid about the same gap from the clinical side of things: recent large trials with EPA and DHA have not reliably demonstrated benefit on hard clinical endpoints, pertinent guidelines do not uniformly recommend EPA and DHA for cardiac patients, and cardiologists in Europe do not routinely use the Index to guide cardiovascular risk reduction. A biomarker can be a genuinely useful predictor of population risk and still not have been proven, in a controlled trial, to be a lever that changes your individual outcome when you pull it.

Genetics explain more of your score than most people assume

One more reason to be cautious about reading a single number as a report card on your diet: research on the Index estimates that dietary intake explains only somewhere between 12% and 25% of the variation in people’s scores, while heredity accounts for roughly 24% on its own.

In plain terms, two people eating close to identical diets can land on meaningfully different results, and a real chunk of that gap isn’t something either of them controlled by what they ate that month. A low score is worth noticing. On its own, it isn’t evidence that you’re doing something wrong.

What actually moves the number

Habitual intake of EPA and DHA — found mainly in fatty fish — is the main lever most people have available, precisely because red blood cell membranes are built from whatever fatty acids have been circulating over the months they’re made. A single fish dinner won’t shift the number; a habitual pattern sustained over months will, since that’s the timescale the test itself is built to reflect.

Plant-based ALA, found in foods like walnuts and flaxseed, is the only omega-3 the U.S. Institute of Medicine has set an intake value for at all — an Adequate Intake of 1.6 grams a day for adult men and 1.1 grams a day for adult women, because there wasn’t enough evidence to set a full Recommended Dietary Allowance. Notably, the Institute of Medicine did not set any comparable intake recommendation specifically for EPA or DHA. The body converts only a small, inefficient fraction of dietary ALA into EPA and DHA, so a diet built around plant sources alone moves an Omega-3 Index by a different and generally smaller amount than one that includes fatty fish directly.

That gap in the official reference values is itself informative. There’s no government-set daily target to compare your test result’s implied intake against — only the research-derived risk bands described above, and your own trend over time.

Why this is graded “moderate”

The core physiological claim here is about as solid as it gets: red blood cell EPA+DHA behaves like a multi-month average of intake, and that’s well established. What keeps this at “moderate” rather than “strong” is everything sitting on top of that fact.

The specific 4% and 8% thresholds are a research proposal from the paper that introduced the test, not an independently ratified clinical guideline. The lab-to-lab variability problem was real enough to require its own standardization effort. And the leap from “this marker predicts population risk in cohort studies” to “changing this marker changes your personal risk” isn’t supported by the same quality of evidence — Cochrane’s high-certainty finding on all-cause mortality points the other way for that leap specifically, even while the underlying association between the marker and coronary risk remains a reasonable and consistently replicated one.

None of that makes the test meaningless. It makes it a genuinely informative long-term biomarker whose target zone is a research hypothesis you’re welcome to take seriously, not a settled clinical fact you should treat as equivalent to your cholesterol panel.